The 12th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.

Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.

AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.

In recent years, several beneficial cell samples and microbial strains have been discovered, engineered, and studied, resulting in scientific discoveries and other technological breakthroughs such as vaccines and medicines benefitting communities all around the world. However, several medical products tend to require very low temperatures for storage, making Ultra-Low Freezers increasingly important to maintain their viability.

German Bayer AG has announced  it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.

 

Building a sustainable future this is what drives us. We are passionate about making smart biotech materials part of everyday life. We believe nature offers better alternatives to existing materials with biofabricated technologies previously unimaginable – enabling our customers to make a true change. 

Avantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF.

The Swedish chief epidemiologist Anders Tegnell plans to move to the World Health Organisation (WHO) in Geneva.

Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad 

While the Nasdaq Biotechnology index saw a huge uplift during the pandemic (+ 77% since March 2020 until reaching a peak in August 2021), it lost 27% during the last six months vs a 11%/4% decline for the Nasdaq Composite and the S&P 500, respectively